Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. (Q39750020)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Mayrel Labrada

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Marilyn Clavell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Yanín Bebelagua

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Joel de León

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mariano R Gabri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Roberto C Veloso

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Vicente Vérez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Luis E Fernández

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

153-162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20088712%20AND%20SRC:MED&resulttype=core&format=json

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Vaccines for tumour prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Therapeutic cancer vaccines: at midway between immunology and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Major and c-series gangliosides in lenticular tissues: mammals to molluscs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

The pattern of mammalian brain gangliosides. 3. Regional and developmental differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Sialic acid concentration of brain gangliosides: variation among eight mammalian species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Cancer vaccines targeting carbohydrate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Lipid Composition of Human Malignant Melanoma Tumors at Various Levels of Malignant Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Role of tumor-associated gangliosides in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Gangliosides shed by tumor cells enhance tumor formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Selectins and other mammalian sialic acid-binding lectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Diversity in the sialic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

N-glycolylneuraminic acid deficiency in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

N-Glycolylneuraminic acid in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Preparative route to N-glycolylneuraminic acid phenyl 2-thioglycoside donor and synthesis of Neu5Gc-alpha-(2-->3')-lactosamine 3-aminopropyl glycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

In situ immunological determination of basic carbohydrate structures of gangliosides on thin-layer plates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Gangliosides and organ-specific metastatic colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Ganglioside composition and histology of a spontaneous metastatic brain tumour in the VM mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Augmenting the immunogenicity of carbohydrate tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084

Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903443084